… Erlotinib (Tarceva™; OSI Pharmaceuticals, Genentech and Roche), a quinazoline derivative
… kinases that has been studied in clinical trials. In a Phase I study, mild diarrhoea and mild …

… The epidermal growth factor receptor (EGFR) mutation rate is low in lung SCC. The aim of
this study was to evaluate the status of erlotinib treatment and EGFR mutation in lung SCC …

… The BR.21 study was a phase 3 trial of erlotinib involving patients who had had progression
… lung cancer. Patients were randomly assigned in a 2:1 ratio to receive 150 mg of erlotinib …

… Erlotinib was well tolerated in this study with the main toxicities … The promising efficacy of
erlotinib monotherapy in this study … Studies investigating the optimal sequence of erlotinib and …

… for advanced non-small-cell lung cancer (NSCLC) is usually … ) tyrosine-kinase inhibitor
erlotinib has proven efficacy and … ; BO18192) study to assess use of erlotinib as maintenance …

… patients in this study received erlotinib as a fourth-line or subsequent treatment, the results
from this study were similar to those of clinical studies. We deduce that erlotinib is effective …

… In the erlotinib study in patients with NSCLC and the gefitinib study … Phase II single-agent
studies with erlotinib, gefitinib, or … combination studies with cetuximab, and one Phase III study …

… contribute to the benefit observed with sequential erlotinib in this study. Indeed, two patients
with EGFR mutations obtained a substantial benefit with sequential erlotinib (PFS, 56 to 82+ …

… study examined the efficacy and safety of erlotinib combined with cisplatin and gemcitabine
for first-line treatment of advanced NSCLC. Overall, the erlotinib … 43 weeks for erlotinib plus …

… received weekly high-dose erlotinib on the current study was 9.5 months and compared …
daily erlotinib on the BR-21 trial, the number of patients treated on the current study was small, …